Oncogene-induced senescence as a new mechanism of disease: The paradigm of Erdheim-Chester disease

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Cavalli, Giulio ^a,b   Biavasco, Riccardo ^b   Borgiani, Bruno ^a   Dagna, Lorenzo ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

BRAF kinases; Erdheim Chester disease; Histiocytosis; Inflammation; Macrophages; Oncogene induced senescence

Indexed keywords

EID: 84905659020     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00281     Document Type: Short Survey

References (50)

1. Chester W. Uber lipoidgranulomatose 1. Virchows Arch Pathol Anat Physiol Klin Med (1930) 279:561-602. doi:10.1007/BF01942684
2. Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis (2013) 72(10):1691-5. doi:10.1136/annrheumdis-2012-202542
3. Haroche J, Arnaud L, Cohen-Aubart F, Hervier B, Charlotte F, Emile J-F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am (2013) 39(2):299-311. doi:10.1016/j.rdc.2013.02.011
4. Della Torre E, Dagna L, Mapelli P, Mellone R, Grazia Sabbadini M. Erdheim-Chester disease: imaging-guided therapeutic approach. Clin Nucl Med (2011) 36(8):704-6. doi:10.1097/RLU.0b013e318217ade7
5. Cavalli G, Berti A, Campochiaro C, Dagna L. Diagnosing Erdheim-Chester disease. Ann Rheum Dis (2013) 72(7):e19. doi:10.1136/annrheumdis-2013-203685
6. Cangi MG, Biavasco R, Cavalli G, Grassini G, Dal-cin E, Campochiaro C, et al. BRAF V600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis (2014):1-7. doi:10.1136/annrheumdis-2013-204924
7. Haroche J, Charlotte F, Arnaud L, von Deimling A, Hélias-Rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood (2012) 120(13):2700-3. doi:10.1182/blood-2012-05-430140
8. Arnaud L, Devilliers H, Peng SL, Mathian A, Costedoat-Chalumeau N, Buckner J, et al. The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev (2012) 12(2):204-9. doi:10.1016/j.autrev.2012.06.005
9. Emile J-F, Charlotte F, Amoura Z, Haroche J. BRAF mutations in Erdheim-Chester disease. J Clin Oncol (2013) 31(3):398. doi:10.1200/JCO.2012.46.9676
10. Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol (2012) 30(32):e331-2. doi:10.1200/JCO.2012.43.2260
11. Haroche J, Cohen-Aubart F, Emile J-F, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood (2013) 121:1495-500. doi:10.1182/blood-2012-07-446286
12. Wilejto M, Abla O. Langerhans cell histiocytosis and Erdheim-Chester disease. Curr Opin Rheumatol (2012) 24(1):90-6. doi:10.1097/BOR.0b013e32834db53e
13. Devouassoux G, Lantuejoul S, Chatelain P, Brambilla E, Brambilla C. Erdheim-Chester disease: a primary macrophage cell disorder. Am J Respir Crit Care Med (1998) 157(2):650-3. doi:10.1164/ajrccm.157.2.97-03109
14. Chetritt J, Paradis V, Dargere D, Adle-Biassehe H, Maurage CA, Mussini JM, et al. Chester-Erdheim disease: a neoplastic disorder. Hum Pathol (1999) 30:1093-6. doi:10.1016/S0046-8177(99)90228-9
15. Al-Quran S, Reith J, Bradley J, Rimsza L. Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature. Mod Pathol (2002) 15(6):666-72. doi:10.1038/modpathol.3880583
16. Vencio EF, Jenkins RB, Schiller JL, Huynh TVT, Wenger DD, Inwards CY, et al. Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol (2007) 31:319-21. doi:10.1097/01.pas.0000213366.33627.a0
17. Stoppacciaro A, Ferrarini M, Salmaggi C, Colarossi C, Praderio L, Tresoldi M, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum (2006) 54:4018-22. doi:10.1002/art.22280
18. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122(3):787-95. doi:10.1172/JCI59643
19. Arnaud L, Gorochov G, Charlotte F, Lvovschi V, Parizot C, Larsen M, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood (2011) 117(10):2783-90. doi:10.1182/blood-2010-10-313510
20. Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M. TNF-a in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology (Oxford) (2014) 53(1):198-200. doi:10.1093/rheumatology/ket246
21. Dagna L, Girlanda S, Langheim S, Rizzo N, Bozzolo EP, Sabbadini MG, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) (2010) 49(6):1203-6. doi:10.1093/rheumatology/kep461
22. Adam Z, Sprláková A, Rehák Z, Koukalová R, Szturz P, Krejcí M, et al. Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxyadenosine and their full remission following treatment with lenalidomide. Klin Onkol (2011) 24(5):367-81.
23. Myra C, Sloper L, Tighe PJ, McIntosh RS, Stevens SE, Gregson RHS, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol (2004) 88(6):844-7. doi:10.1136/bjo.2003.035584
24. Hervier B, Arnaud L, Charlotte F, Wechsler B, Piette JC, Amoura Z, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-a. Semin Arthritis Rheum (2012) 41(6):907-13. doi:10.1016/j.semarthrit.2011.11.004
25. Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn J-E, Wechsler B, et al. CNS involvement and treatment with interferon-a are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood (2011) 117(10):2778-82. doi:10.1182/blood-2010-06-294108
26. Jakobson AM, Kreuger A, Hagberg H, Sundström C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet (1987) 2(8574):1520-1. doi:10.1016/S0140-6736(87)92649-3
27. Löhr HF, Gödderz W, Wölfe T, Heike M, Knuth A, Meyer Zum Büschenfelde KH, et al. Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer (1995) 31A(13-14):2427-8.
28. Luft T, Luetjens P, Hochrein H, Toy T, Masterman K-A, Rizkalla M, et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol (2002) 14(4):367-80. doi:10.1093/intimm/14.4.367
29. Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol (1998) 161(4):1947-53.
30. Aouba A, Georgin-Lavialle S, Pagnoux C, Martin Silva N, Renand A, Galateau-Salle F, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood (2010) 116(20):4070-6. doi:10.1182/blood-2010-04-279240
31. Aubert O, Aouba A, Deshayes S, Georgin-Lavialle S, Rieu P, Hermine O. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine (2013) 80(2):206-7. doi:10.1016/j.jbspin.2012.07.005
32. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine (2014) 81(2):175-7. doi:10.1016/j.jbspin.2013.06.013
33. Dagna L, Corti A, Langheim S, Guglielmi B, De Cobelli F, Doglioni C, et al. Tumor necrosis factor a as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol (2012) 30(28):e286-90. doi:10.1200/JCO.2012.41.9911
34. Badalian-Very G, Vergilio J-A, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 116(11):1919-23. doi:10.1182/blood-2010-04-279083
35. Diamond EL, Abdel-Wahab O, Pentsova E, Borsu L, Chiu A, Teruya-Feldstein J, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood (2013) 122(6):1089-91. doi:10.1182/blood-2013-02-482984
36. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364(26):2507-16. doi:10.1056/NEJMoa1103782
37. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 105(8):3041-6. doi:10.1073/pnas.0711741105
38. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 107(33):14903-8. doi:10.1073/pnas.1008990107
39. Oldenburg RP, Liu MS, Kolodney MS. Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol (2008) 128(2):398-402. doi:10.1038/sj.jid.5700920
40. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J (2005) 392(Pt 2):249-61. doi:10.1042/BJ20050908
41. Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. Ann Pharmacother (2011) 45(11):1399-405. doi:10.1345/aph.1Q363
42. Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review). Oncol Rep (2009) 22(4):671-81. doi:10.3892/or_00000487
43. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol (2010) 80(5):561-7. doi:10.1016/j.bcp.2010.03.019
44. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 364(24):2305-15. doi:10.1056/NEJMoa1014209
45. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med (2006) 355:1037-46. doi:10.1056/NEJMra062285
46. Michaloglou C, Vredeveld LCW, Soengas MS, Denoyelle C, Kuilman T, van der Horst CMAM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 436(7051):720-4. doi:10.1038/nature03890
47. Kuilman T, Michaloglou C, Vredeveld LCW, Douma S, Van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell (2008) 133:1019-31. doi:10.1016/j.cell.2008.03.039
48. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, et al. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One (2013) 8(1):e54302. doi:10.1371/journal.pone.0054302
49. Chilosi M, Facchetti F, Caliò A, Zamò A, Brunelli M, Martignoni G, et al. Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis. Leuk Lymphoma (2014). doi:10.3109/10428194.2014.887713
50. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest (2013) 123(3):966-72. doi:10.1172/JCI64098